Sep 8, 2026 06:26PM
Sep 8, 2026 06:25PM
Feb 9, 2022 09:53AM
Nov 22, 2021 09:00AM
Nov 4, 2021 05:00PM
Apr 30, 2021 08:00AM
Apr 8, 2021 08:30AM Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
Mar 31, 2021 05:02PM
Feb 18, 2021 07:00AM
Feb 12, 2021 12:41PM
Feb 10, 2021 07:00AM
Feb 9, 2021 04:03PM
Feb 9, 2021 04:03PM
Jan 27, 2021 05:30PM Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelet
Jan 7, 2021 05:30PM
Dec 17, 2020 04:06PM
Dec 17, 2020 04:05PM
Dec 17, 2020 04:05PM
Nov 18, 2020 06:00PM
Oct 19, 2020 07:00AM
Sep 29, 2020 07:00AM Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
Sep 24, 2020 07:06AM
Sep 24, 2020 07:00AM
Aug 11, 2020 05:00PM
Jun 30, 2020 07:00AM
Jun 29, 2020 09:06AM
Jun 16, 2020 07:00AM
Jun 15, 2020 01:48PM Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
Feb 28, 2020 07:00AM
Feb 10, 2020 07:00AM
Jan 14, 2020 07:00AM
Jan 13, 2020 07:00AM
Jan 13, 2020 07:00AM
Dec 17, 2019 05:30PM
Dec 12, 2019 06:00PM Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coro
Dec 5, 2019 05:29PM
Nov 11, 2019 06:30AM
Oct 7, 2019 08:02AM
Oct 7, 2019 08:00AM
Oct 3, 2019 06:00PM
Sep 30, 2019 06:30AM
Sep 17, 2019 09:59AM Medicure Announces Launch of New and Improved ReDS™ PRO
Sep 17, 2019 07:00AM
Sep 10, 2019 08:00AM
Sep 4, 2019 08:00AM
Aug 21, 2019 05:00PM
Jul 16, 2019 08:00AM
Jul 15, 2019 08:06AM
Jul 15, 2019 08:00AM Mereo BioPharma Announces Successful Type B Meeting with U.S. FDA and Outlines Accelerated Approval Pathway for Navicixizumab in Advanced Ovarian Cancer
Jun 13, 2019 08:00AM

330,722 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All